Ahmet ŞEN, Başar ERDİVANLI, Neslihan HATINOGLU, Abdullah OZDEMİR

Evaluation of colistin-associated acute renal failure in intensive care unit

Aim: Colistin’s parenteral use was limited due to nephrotoxicity related to decreased renal perfusion, nephrotoxins and ischemiareperfusioninjury. Colistin became popular again because of multiple drug resistance.This study aimed to retrospectively evaluate the characteristics of intensive care patient groups with and without colistin-inducedacute kidney injury.Material and Methods: Following approval of local ethics committee, information of the patients, who were treated in the anesthesiaand surgical intensive care units between 01/01/2016 and 30/06/2017, were analyzed retrospectively.Results: Twenty patients (59%) developed acute kidney injury during colistin treatment. No statistically significant difference wasobserved between the groups with and without acute kidney injury in terms of age, gender and duration of stay in the intensive careunit, however, patients with acute kidney injury were found to be older and stayed in the intensive care unit for a longer period oftime. The comparison made between the groups in terms of inotropic agent use showed that the duration of inotropic agent use wasstatistically longer in the acute kidney injury group.Discussion: Rate of colistin-induced acute kidney injury varies between 5-55%. In addition, fluid balance of patients is importantin acute kidney injury development. Fluid therapy, hourly urine output and central venous pressure trends of the patients should beclosely monitored particularly when nephrotoxic medicines are used.There is a need for large-scale studies with more advanced methodologies for the early detection and prevention of colistin-inducednephrotoxicity.

PDF

___

1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multi-drug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
3. Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004;286:913-22.
4. Balkan II, Dogan M, Durdu B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014;46:678-85.
5. Kwa A, Kasiakou SK, Tam VH, et al. Polymyxin B similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther 2007;5:811-21.
6. Li J, Turnidge J, Milne R, et al. In vitro pharma¬codynamic properties of colistin and colistin methanosulphonate against Pseudomonas aeruginosa isolates from patients with cystic fibsosis. Antimicrob Agents Chemother 2001;45:781-5.
7. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:19-36.
8. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated ne-phrotoxi¬city in a large academic health system. Clin Infect Dis 2011;53:879-84.
9. Cho AY, Yoon HJ, Lee JC, Lee, et al. Comparison of clinical characteristics of patients with acute kidney injury after intravenous versus inhaled colistin therapy. Kidney Res Clin Pract 2016;35:229-32.
10. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilation associated pneumonia: a matched case-control study. Intensive Care Med 2007;33:1162-7.
11. Deryke CA, Crawford AJ, Uddin N, et al. Colistin dosing and nephrotoxicity in a large commu-nity teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5.
12. Gul S, Kuscu F, Aydemir H, et al. Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey. Jpn J Infect Dis 2016;69:109-12.
13. Inci A, Toker MK, Bicer IG, et al. Determination of colistin-related nephrotoxicity and risk fac-tors in intensive care unit. North Clin Istanb 2018;5:120-4.
14. Arslan Zİ, Özbudak E, Türkyılmaz N, et al. Evaluation of the use of colistin on nephrotoxicity and mortality in the intensive care unit. Turkiye Klinikleri J Anest Reanim 2015;13:21-4.
15. Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistinresistant gram-negative bacteria: a matched casecontrol study. Crit Care Med 2008;36:807-11.
16. Lee YJ, Wi YM, Kwon YJ, et al. Association between colistin dose and development of nephrotoxi-city. Crit Care Med 2015;43:1187-93.